The dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis

被引:24
作者
Werner, C. M. [1 ]
Schirmer, S. H. [1 ]
Gensch, C. [1 ]
Pavlickova, V. [1 ]
Poess, J. [1 ]
Wright, M. B. [2 ]
Boehm, M. [1 ]
Laufs, U. [1 ]
机构
[1] Univ Klinium Saarlandes, Klin Innere Med Kardiol Angiol & Internist Intens, D-66421 Homburg, Germany
[2] F Hoffmann La Roche & Cie AG, PRED, DTA Cardiovasc & Metab, Basel, Switzerland
关键词
PPAR; agonist; endothelial progenitor cells; circulating angiogenic cells; endothelial function; arteriogenesis; endothelial NO synthase; atherosclerosis; aleglitazar; COLLATERAL ARTERY GROWTH; HEART-RATE REDUCTION; CARDIOVASCULAR-DISEASE; NEOINTIMA FORMATION; MIGRATORY ACTIVITY; DIABETES-MELLITUS; GAMMA; EXPRESSION; REENDOTHELIALIZATION; INHIBITOR;
D O I
10.1111/bph.12608
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and PurposeAleglitazar is a dual PPAR/ agonist but little is known about its effects on vascular function and atherogenesis. Hence, we characterized its effects on circulating angiogenic cells (CAC), neoangiogenesis, endothelial function, arteriogenesis and atherosclerosis in mice. Experimental ApproachC57Bl/6 wild-type (WT, normal chow), endothelial NOS (eNOS)(-/-) (normal chow) and ApoE(-/-) (Western-type diet) mice were treated with aleglitazar (10mgkg(-1)day(-1), i.p.) or vehicle. Key ResultsAleglitazar enhanced expression of PPAR and PPAR target genes, normalized glucose tolerance and potently reduced hepatic fat in ApoE(-/-) mice. In WT mice, but not in eNOS(-/-), aleglitazar up-regulated Sca-1/VEGFR2-positive CAC in the blood and bone marrow and up-regulated diLDL/lectin-positive CAC. Aleglitazar augmented CAC migration and enhanced neoangiogenesis. In ApoE(-/-) mice, aleglitazar up-regulated CAC number and function, reduced markers of vascular inflammation and potently improved perfusion restoration after hindlimb ischaemia and aortic endothelium-dependent vasodilatation. This was associated with markedly reduced formation of atherosclerotic plaques. In human cultured CAC from healthy donors and patients with coronary artery disease with or without diabetes mellitus, aleglitazar increased migration and colony-forming units in a concentration-dependent manner. Furthermore, oxidative stress-induced CAC apoptosis and expression of p53 were reduced, while telomerase activity and expression of phospho-eNOS and phospho-Akt were elevated. Comparative agonist and inhibitor experiments revealed that aleglitazar's effects on CAC migration and colony-forming units were mediated by both PPAR and PPAR signalling and required Akt. Conclusions and ImplicationsAleglitazar augments the number, function and survival of CAC, which correlates with improved vascular function, enhanced arteriogenesis and prevention of atherosclerosis in mice.
引用
收藏
页码:2685 / 2703
页数:19
相关论文
共 52 条
[1]   Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia [J].
Adams, V ;
Lenk, K ;
Linke, A ;
Lenz, D ;
Erbs, S ;
Sandri, M ;
Tarnok, A ;
Gielen, S ;
Emmrich, F ;
Schuler, G ;
Hambrecht, R .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (04) :684-690
[2]   THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: NUCLEAR HORMONE RECEPTORS [J].
Alexander, Stephen P. H. ;
Benson, Helen E. ;
Faccenda, Elena ;
Pawson, Adam J. ;
Sharman, Joanna L. ;
Spedding, Michael ;
Peters, John A. ;
Harmar, Anthony J. .
BRITISH JOURNAL OF PHARMACOLOGY, 2013, 170 (08) :1652-1675
[3]   Isolation of putative progenitor endothelial cells for angiogenesis [J].
Asahara, T ;
Murohara, T ;
Sullivan, A ;
Silver, M ;
vanderZee, R ;
Li, T ;
Witzenbichler, B ;
Schatteman, G ;
Isner, JM .
SCIENCE, 1997, 275 (5302) :964-967
[4]   PPARα Is Essential for Microparticle-Induced Differentiation of Mouse Bone Marrow-Derived Endothelial Progenitor Cells and Angiogenesis [J].
Benameur, Tarek ;
Tual-Chalot, Simon ;
Andriantsitohaina, Ramaroson ;
Martinez, Maria Carmen .
PLOS ONE, 2010, 5 (08)
[5]   Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes [J].
Benardeau, Agnes ;
Benz, Joerg ;
Binggeli, Alfred ;
Blum, Denise ;
Boehringer, Markus ;
Grether, Uwe ;
Hilpert, Hans ;
Kuhn, Bernd ;
Maerki, Hans Peter ;
Meyer, Markus ;
Puentener, Kurt ;
Raab, Susanne ;
Ruf, Armin ;
Schlatter, Daniel ;
Mohr, Peter .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (09) :2468-2473
[6]   Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets [J].
Brown, Jonathan D. ;
Plutzky, Jorge .
CIRCULATION, 2007, 115 (04) :518-533
[7]   Therapeutic Potential of Aleglitazar, a New Dual PPAR-α/γ Agonist Implications for Cardiovascular Disease in Patients with Diabetes Mellitus [J].
Cavender, Matthew A. ;
Lincoff, A. Michael .
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2010, 10 (04) :209-216
[8]   PPAR-α and PPAR-γ agonists for type 2 diabetes [J].
Charbonnel, Bernard .
LANCET, 2009, 374 (9684) :96-98
[9]   Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice [J].
Custodis, Florian ;
Baumhaekel, Magnus ;
Schlimmer, Nils ;
List, Franka ;
Gensch, Christoph ;
Boehm, Michael ;
Laufs, Ulrich .
CIRCULATION, 2008, 117 (18) :2377-2387
[10]   Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors [J].
Dietz, Michel ;
Mohr, Peter ;
Kuhn, Bernd ;
Maerki, Hans Peter ;
Hartman, Peter ;
Ruf, Armin ;
Benz, Joerg ;
Grether, Uwe ;
Wright, Matthew B. .
CHEMMEDCHEM, 2012, 7 (06) :1101-1111